nemtabrutinib (MK-1026) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   135 News 


123»
  • ||||||||||  nemtabrutinib (MK-1026) / Merck (MSD), Rituxan (rituximab) / Roche
    Enrollment open, Trial completion date, Trial primary completion date:  Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma (clinicaltrials.gov) -  Jan 10, 2025   
    P2,  N=27, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Feb 2026 --> Jan 2027 | Trial primary completion date: Feb 2026 --> Jan 2027
  • ||||||||||  nemtabrutinib (MK-1026) / Merck (MSD)
    Trial completion date, Trial primary completion date:  A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015) (clinicaltrials.gov) -  Oct 10, 2024   
    P1,  N=16, Recruiting, 
    The median PFS for ven as first tx following ncBTKi dc was 23 months in this largely ven-na Trial completion date: Feb 2025 --> Aug 2025 | Trial primary completion date: Feb 2025 --> Aug 2025
  • ||||||||||  Jaypirca (pirtobrutinib) / Eli Lilly, nemtabrutinib (MK-1026) / Merck (MSD)
    MODULE 4: Integration of Noncovalent BTK Inhibitors into the Management of R/R CLL (Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH; In-Person; Virtual) -  Oct 5, 2024 - Abstract #ASH2024ASH_78;    
    Trial completion date: Feb 2025 --> Aug 2025 | Trial primary completion date: Feb 2025 --> Aug 2025 This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd and Eli Lilly.Clinical and biological factors guiding decision-making for patients with R/R CLL; current role of rechallenge with an agent or class of agents received in a prior line of therapy Mechanistic similarities and differences between noncovalent and covalent BTK inhibitors; implications for efficacy and tolerability Antitumor activity documented with pirtobrutinib from the Phase I/II BRUIN study in patients with R/R CLL, including those who experience disease progression on covalent BTK inhibitors Spectrum, frequency and severity of toxicities with pirtobrutinib relative to covalent BTK inhibitors Recent FDA approval and current clinical role of pirtobrutinib for R/R CLL Ongoing Phase III trials (eg, BRUIN CLL-313, BRUIN CLL-314, BRUIN CLL-321, BRUIN CLL-322) evaluating pirtobrutinib for CLL Similarities and differences between pirtobrutinib and nemtabrutinib; early efficacy and safety data with nemtabrutinib for R/R CLL and ongoing Phase III evaluation for treatment-na
  • ||||||||||  nemtabrutinib (MK-1026) / Merck (MSD)
    Trial completion date, Trial primary completion date:  A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005) (clinicaltrials.gov) -  Sep 22, 2024   
    P1,  N=12, Active, not recruiting, 
    This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd and Eli Lilly.Clinical and biological factors guiding decision-making for patients with R/R CLL; current role of rechallenge with an agent or class of agents received in a prior line of therapy Mechanistic similarities and differences between noncovalent and covalent BTK inhibitors; implications for efficacy and tolerability Antitumor activity documented with pirtobrutinib from the Phase I/II BRUIN study in patients with R/R CLL, including those who experience disease progression on covalent BTK inhibitors Spectrum, frequency and severity of toxicities with pirtobrutinib relative to covalent BTK inhibitors Recent FDA approval and current clinical role of pirtobrutinib for R/R CLL Ongoing Phase III trials (eg, BRUIN CLL-313, BRUIN CLL-314, BRUIN CLL-321, BRUIN CLL-322) evaluating pirtobrutinib for CLL Similarities and differences between pirtobrutinib and nemtabrutinib; early efficacy and safety data with nemtabrutinib for R/R CLL and ongoing Phase III evaluation for treatment-na Trial completion date: Apr 2025 --> Apr 2027 | Trial primary completion date: Apr 2025 --> Apr 2027
  • ||||||||||  Novel Approaches to Richter Syndrome (LEVEL 3, GENERAL ASSEMBLY) -  Jul 5, 2024 - Abstract #SOHO2024SOHO_193;    
    P1/2, P2
    Trials are also ongoing with bispecific antibodies, such as the CD20-directed CD3 T-cell engagers, epcoritamab (NCT04623541),14 glofitamab (NCT06043674), and mosunetuzumab (NCT05207670),15 which, like CAR-T therapy, have all shown efficacy in standard DLBCL. As evidenced, significant efforts employing a multifaceted array of approaches are underway for the treatment of RS, generating hope for the possibility of improved outcomes for this aggressive disease.
  • ||||||||||  Review, Journal:  Waldenstr (Pubmed Central) -  Dec 6, 2023   
    Not yet recruiting --> Recruiting With the worldwide approval of the oral covalent Bruton tyrosine kinase (BTK) inhibitors ibrutinib and zanubrutinib for treating patients with Waldenstr
  • ||||||||||  Review, Journal, IO biomarker:  SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. (Pubmed Central) -  Sep 25, 2023   
    While these agents have led to an improved safety profile in comparison to Ibrutinib (both acalabrutinib and zanubrutinib), and improved efficacy (zanubrutinib), intolerance occasionally occurs, and resistance remains a challenge...By removing BTK, as opposed to inhibiting it, these drugs could remain efficacious irrespective of BTK resistance mutations, however clinical data are limited at this time. This review summarizes the evolution and ongoing development of newer BTKi and BTK degraders in the management of CLL, with a focus of future directions in this field, including how emerging clinical data could inform therapeutic sequencing in CLL management.
  • ||||||||||  MODULE 5: Promising Investigational Agents and Strategies (Omni San Diego, Grand Ballroom (Level 2), 4) -  Sep 23, 2023 - Abstract #ASH2023ASH_267;    
    Supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, and Lilly. Biological rationale for the investigation of CD19-directed chimeric antigen receptor T-cell therapy for patients with CLL Published and emerging findings with lisocabtagene maraleucel (liso-cel) monotherapy in the Phase I/II TRANSCEND CLL 004 trial; rates of complete response compared to historical controls Early findings with liso-cel in combination with ibrutinib for heavily pretreated CLL Mechanism of action of nemtabrutinib; early efficacy and safety data with nemtabrutinib for R/R CLL and ongoing Phase III evaluation for treatment-na
  • ||||||||||  Review, Journal:  Non-Covalent Bruton's Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia. (Pubmed Central) -  Jul 29, 2023   
    Several ncBTKis have been studied preclinically and in clinical trials, including pirtobrutinib and nemtabrutinib...Novel therapeutic strategies are being investigated to address the treatment of patients following disease progression on ncBTKis. Such strategies include novel agents (BTK degraders, bispecific antibody therapy, CAR T-cell therapy, PKC-beta inhibitors) as well as combination approaches incorporating a ncBTKi (e.g., pirtobrutinib and venetoclax) that may help overcome this acquired resistance.
  • ||||||||||  Review, Journal, IO biomarker:  Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). (Pubmed Central) -  Jun 6, 2023   
    The second-generation more selective BTK inhibitors (acalabrutinib and zanubrutinib) have shown improved safety profile compared to ibrutinib...The novel non-covalent BTK inhibitors such as pirtobrutinib (Loxo-305) and nemtabrutinib (ARQ 531) are showing promising activities for relapsed CLL refractory to prior covalent BTKi...Patients with relapsed CLL now have more options for the treatment of the disease. The choice of therapy is best individualized especially in the absence of direct comparisons of targeted therapies, and the coming years will bring more data on the best sequence of use of the therapeutic agents.
  • ||||||||||  nemtabrutinib (MK-1026) / Merck (MSD), Imbruvica (ibrutinib) / AbbVie, J&J
    Journal:  Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy. (Pubmed Central) -  May 22, 2023   
    Moreover, compound 3e suppressed the cell growth more potently than the small molecule inhibitors ibrutinib and ARQ-531 in several cells. Furthermore, compound 3e with the rigid linker displayed a significantly improved metabolic stability profile with the T increased to more than 145